Lidocaine liposome modified with folic acid suppresses the proliferation and motility of glioma cells via targeting the PI3K/AKT pathway

• DOI: 10.3892/etm.2021.10457
• Publication Date: 2021-07-15T20:55:16Z
• Authors: Dedong Li; Xuewei Yang; Bo Li; Chenyi Yang; Jian Sun; Mingdong Yu; Haiyun Wang; Yuechun Lu
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Articles; 3. Good health

Glioma is life‑threatening tumor of the central nervous system. Although lidocaine usually used as local anesthetic, it also has antitumor effects. However, its clinical application in glioma hampered by limited distribution to brain. The aim present study was enhance ability penetrate blood‑brain barrier (BBB) target and investigate mechanism. A folic acid (FA)‑modified lidocaine‑carrying liposome (Lid‑FA‑Lip) prepared, particle size, ζ potential, encapsulation efficiency, release profile stability hemolytic effect were characterized vitro. targeting capacity activities Lid‑FA‑Lip investigated <em>in vitro</em> vivo</em>. results indicated that modification liposomes with FA significantly improved cross BBB an model increased uptake U87 cells. Additionally, suppressed motility cells stimulated apoptosis. Furthermore, confirmed targeted PI3K/AKT pathway growth xenografts mice. In summary, demonstrated a promising liposomal formulation may provide therapeutic effects on glioma, mediated via pathway.